Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Roche Holding AG Basel American Depositary Shares
(OP:
RHHBY
)
51.09
+0.51 (+1.00%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 8, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,532,360
Open
50.75
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
50.59
Today's Range
50.41 - 51.09
52wk Range
35.07 - 60.85
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Genentech to Present Extensive Data Showcasing Its Industry-Leading Ophthalmology Portfolio at ARVO 2026
April 30, 2026
From
Genentech
Via
Business Wire
Genentech Partners With Comedy Icon Damon Wayans and diaTribe to Address Diabetes-Related Vision Loss With ‘All Eyes on DME’ Campaign
April 24, 2026
From
Genentech
Via
Business Wire
Performance
YTD
-0.7%
-0.7%
1 Month
+2.0%
+2.0%
3 Month
-11.5%
-11.5%
6 Month
+21.8%
+21.8%
1 Year
+30.6%
+30.6%
More News
Read More
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Leads Shift Toward Pipeline-Driven Valuation in Biotech Sector
April 22, 2026
Via
Investor Brand Network
Topics
Intellectual Property
Advancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition
April 22, 2026
From
BioMedWire
Via
GlobeNewswire
Genentech’s Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMS
April 21, 2026
From
Genentech
Via
Business Wire
Genentech’s Enspryng (Satralizumab) Reduces Risk of Relapses by 68% Demonstrating Potential to Become First Treatment for MOGAD
April 21, 2026
From
Genentech
Via
Business Wire
FDA Accepts Application for Genentech’s Gazyva for the Treatment of the Most Common Form of Lupus
April 21, 2026
From
Genentech
Via
Business Wire
Could AbbVie Crash Lilly's Weight‑Loss Party?
↗
April 14, 2026
Via
The Motley Fool
The Science of Scale: An In-Depth Look at Regeneron Pharmaceuticals (REGN) in 2026
April 13, 2026
Via
Finterra
Topics
Earnings
Economy
Intellectual Property
C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)
April 09, 2026
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
Biogen Acquires Apellis Pharmaceuticals in $5.6 Billion Move into Immunology
April 06, 2026
Via
MarketMinute
The "Liberation Day" Shockwave: US Finalizes 100% Tariffs on Branded Pharmaceutical Imports
April 06, 2026
Via
MarketMinute
Topics
Economy
World Trade
The Great Metabolic Land Grab: Why Viking and Structure Have Become Big Pharma’s 'Irresistible' Targets
April 03, 2026
Via
MarketMinute
Topics
Intellectual Property
Trump Issues Landmark Executive Order: 100% Tariffs on Imported Patented Drugs to Force Onshoring
April 03, 2026
Via
MarketMinute
Topics
Economy
Government
Lawsuit
Regeneron Pharmaceuticals: The Scientific Juggernaut Navigating a High-Stakes Transformation
April 03, 2026
Via
Finterra
Topics
Economy
Intellectual Property
World Trade
Merck’s Oncology Empire Expands: Keytruda Secures Pivotal European Commission Approval for Recurrent Ovarian Cancer
April 02, 2026
Via
MarketMinute
Topics
Intellectual Property
The Trillion-Dollar Treatment: A Deep Dive into Eli Lilly and Company (LLY)
April 02, 2026
Via
Finterra
Topics
Artificial Intelligence
Economy
Intellectual Property
Biogen Acquires Apellis Pharmaceuticals in $5.6 Billion Deal After Clinical Success
April 01, 2026
Via
MarketMinute
United Therapeutics Surges 14% on Groundbreaking Tyvaso Phase 3 Results for IPF
March 31, 2026
Via
MarketMinute
The $1 Trillion Goliath: Why Eli Lilly’s $6.3B Centessa Bet Defines the Future of Neuroscience
March 31, 2026
Via
Finterra
Topics
Economy
Intellectual Property
AstraZeneca (AZN) Shares Rally After Breakthrough Chronic Lung Disease Trial Results
March 27, 2026
Via
MarketMinute
Topics
Intellectual Property
Kodiak Sciences Surges 19% as Phase 3 GLOW2 Trial Delivers Vital Win for Diabetic Retinopathy Treatment
March 26, 2026
Via
MarketMinute
Sarepta Therapeutics (SRPT) Stock Surges 34.98% on Breakthrough Clinical Data
March 26, 2026
Via
MarketMinute
Merck & Co. (MRK) 2026 Analysis: Navigating the Keytruda Cliff with Pipeline-Driven Resilience
March 25, 2026
Via
Finterra
Topics
Artificial Intelligence
Economy
Intellectual Property
Retirees: Collect a High Dividend While Diversifying Your Portfolio With This ETF
↗
March 24, 2026
Via
The Motley Fool
Topics
ETFs
Retirement
Frequently Asked Questions
Is Roche Holding AG Basel American Depositary Shares publicly traded?
Yes, Roche Holding AG Basel American Depositary Shares is publicly traded.
What exchange does Roche Holding AG Basel American Depositary Shares trade on?
Roche Holding AG Basel American Depositary Shares trades on the OTC Traded
What is the ticker symbol for Roche Holding AG Basel American Depositary Shares?
The ticker symbol for Roche Holding AG Basel American Depositary Shares is RHHBY on the OTC Traded
What is the current price of Roche Holding AG Basel American Depositary Shares?
The current price of Roche Holding AG Basel American Depositary Shares is 51.09
When was Roche Holding AG Basel American Depositary Shares last traded?
The last trade of Roche Holding AG Basel American Depositary Shares was at 05/08/26 04:00 PM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
